

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Innate Immunity and Experimental Crohn's Disease.

*Date:* December 17, 2010.

*Time:* 10 a.m. to 12:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Paul A. Rushing, PhD, Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 747, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8895, [rushingp@extra.niddk.nih.gov](mailto:rushingp@extra.niddk.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: November 8, 2010.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010-28706 Filed 11-12-10; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Recombinant DNA Advisory Committee.

*Date:* December 7-8, 2010.

*Time:* December 7, 2010, 12 p.m. to 6 p.m.

*Agenda:* The NIH Recombinant DNA Advisory Committee will review selected human gene transfer protocols, an

application to certify a new host-vector system for *K. lactis* under Appendix I of the NIH Guidelines for Research Involving Recombinant DNA Molecules and discuss related data management activities. Please check the meeting agenda at [http://oba.od.nih.gov/rdna\\_rac/rac\\_meetings.html](http://oba.od.nih.gov/rdna_rac/rac_meetings.html).

*Place:* Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Time:* December 8, 2010, 8 a.m. to 12:30 p.m.

*Agenda:* The NIH RAC will discuss selected human gene transfer protocols, and related data management activities. Please check the meeting agenda at [http://oba.od.nih.gov/rdna\\_rac/rac\\_meetings.html](http://oba.od.nih.gov/rdna_rac/rac_meetings.html) for more information.

*Place:* Hilton Washington/Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Chezelle George, Office of Biotechnology Activities, Office of Science Policy/OD, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892. 301-496-9838.

[georgec@od.nih.gov](mailto:georgec@od.nih.gov).

Information is also available on the Institute's/Center's home page: <http://oba.od.nih.gov/rdna/rdna.html>, where an agenda and any additional information for the meeting will be posted when available.

OMB's "Mandatory Information Requirements for Federal Assistance Program Announcements" (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: November 5, 2010.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010-28704 Filed 11-12-10; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Advisory Committee on Training in Primary Care Medicine and Dentistry

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice of meeting cancellation.

**SUMMARY:** Notice is hereby given of the cancellation of the Advisory Committee on Training in Primary Care Medicine and Dentistry, November 15, 2010, 8:30 a.m. to 4:30 p.m., and November 16, 2010, 8 a.m. to 2 p.m., at the Hilton Washington DC/Rockville Executive Meeting Center, 1750 Rockville Pike, Rockville, MD 20910, which was published in the **Federal Register** on October 19, 2010, FR Doc. 2010-26205 (75 FR 64318).

Dated: November 8, 2010.

**Robert Hendricks,**

*Director, Division of Policy and Information Coordination.*

[FR Doc. 2010-28693 Filed 11-10-10; 4:15 pm]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

**Disease, Disability, and Injury Prevention and Control; Special Emphasis Panel: Epi-Centers for the Prevention of Healthcare-Associated Infections, Antimicrobial Resistance and Adverse Events, Funding Opportunity Announcement C111-001; Initial Review**

*Correction:* This notice was published in the **Federal Register** on September 14, 2010, Volume 75, Number 177, page 55803. The location of the meeting has been changed to the following:

*Place:* 12 Executive Park Drive, Atlanta, Georgia 30333.

*Contact Person for More Information:*

Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road, NE., Mailstop E60, Atlanta, GA 30333, Telephone: (404) 498-2293.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: November 4, 2010.

**Elaine L. Baker,**

Director, Management Analysis and Services  
Office, Centers for Disease Control and  
Prevention.

[FR Doc. 2010-28597 Filed 11-12-10; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Board of Scientific Counselors, Office of Infectious Diseases, (BSC, OID)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

*Time and Date:* 8:30 a.m.–5 p.m.,  
December 6, 2010.

*Place:* CDC, Global Communications  
Center, 1600 Clifton Road, NE., Building 19,  
Auditorium B1–B2, Atlanta, Georgia 30333.

*Status:* Open to the public, limited only by  
the space available.

*Purpose:* The BSC, OID, provides advice  
and guidance to the Secretary, Department of  
Health and Human Services; the Director,  
CDC; the Director, OID; and the Directors of  
the National Center for Immunization and  
Respiratory Diseases, the National Center for  
Emerging and Zoonotic Infectious Diseases,  
and the National Center for HIV/AIDS, Viral  
Hepatitis, STD, and TB Prevention, CDC, in  
the following areas: strategies, goals, and  
priorities for programs; research within the  
national centers; and overall strategic  
direction and focus of OID and the national  
centers.

*Matters to be Discussed:* The agenda will  
include OID and center updates, followed by  
a focused discussion to solicit  
recommendations from the board on a  
strategic document designed to increase the  
public health impact of CDC's infectious  
disease prevention and control efforts.

Agenda items are subject to change as  
priorities dictate.

*Contact Person for More Information:*  
Robin Moseley, M.A.T., Designated Federal  
Officer, OID, CDC, 1600 Clifton Road, NE.,  
Mailstop D10, Atlanta, Georgia 30333,  
Telephone: (404)639-4461.

The Director, Management Analysis and  
Services office has been delegated the  
authority to sign **Federal Register** notices  
pertaining to announcements of meetings and  
other committee management activities for  
both CDC and the Agency for Toxic  
Substances and Disease Registry.

Dated: November 4, 2010.

**Elaine L. Baker,**

Director, Management Analysis and Services  
Office, Centers for Disease Control and  
Prevention.

[FR Doc. 2010-28581 Filed 11-12-10; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of Biotechnology Activities Recombinant DNA Research: Proposed Actions Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)

**ACTION:** Notice of consideration of  
proposed actions under the *NIH  
Guidelines*.

**SUMMARY:** A request to certify  
*Kluyveromyces lactis* as a new host-  
vector system has been submitted to the  
NIH Office of Biotechnology Activities  
(OBA). The data to be considered for  
certifying a new host-vector system can  
be found in Appendix I of the *NIH  
Guidelines*. A new host-vector system  
may be certified only after review by the  
NIH Recombinant DNA Advisory  
Committee (RAC) and specifically  
approved by the NIH Director as a Major  
Action.

Part of this request is to exempt from  
the *NIH Guidelines* certain types of  
research when performed in *K. lactis*, if  
*K. lactis* and its affiliated plasmids meet  
the requirements for certification as a  
host-vector system. Research that is  
exempt from the *NIH Guidelines* when  
performed with other certified host-  
vector systems can be found in  
Appendix C of the *NIH Guidelines*.

**DATES:** The public is encouraged to  
submit written comments on these  
proposed actions. Comments may be  
submitted to OBA in paper or electronic  
form at the OBA mailing, fax, and e-mail  
addresses shown below under the  
heading **FOR FURTHER INFORMATION  
CONTACT**. The NIH will consider all  
comments submitted by December 1,  
2010. Written comments submitted by  
December 1, 2010 will be reproduced  
and distributed to the RAC for  
consideration at its December 7–8, 2010  
meeting. In addition, an opportunity for  
public comment will be provided at that  
meeting. Please check the meeting  
agenda for the time of this discussion  
([http://oba.od.nih.gov/rdna\\_rac/  
rac\\_meetings.html](http://oba.od.nih.gov/rdna_rac/rac_meetings.html)). All written  
comments received in response to this  
notice will be available for public  
inspection at the NIH OBA office, 6705  
Rockledge Drive, Suite 750, Bethesda,  
MD 20892 (telephone, 301-496-9838),  
weekdays between the hours of 8:30  
a.m. and 5 p.m.

**FOR FURTHER INFORMATION CONTACT:**  
OBA by e-mail at [oba@od.nih.gov](mailto:oba@od.nih.gov), or  
telephone at 301-496-9838, if you have  
questions, or require additional

information about these proposed  
actions. Comments may be submitted to  
the same e-mail address or by fax at  
301-496-9839 or sent by U.S. mail to  
the Office of Biotechnology Activities,  
National Institutes of Health, 6705  
Rockledge Drive, Suite 750, MSC 7985,  
Bethesda, Maryland 20892-7985. For  
additional information about the RAC  
meeting at which these proposed  
actions will be deliberated, please visit  
the NIH OBA Web site at: [http://  
oba.od.nih.gov/oba/index.html](http://oba.od.nih.gov/oba/index.html).

**SUPPLEMENTARY INFORMATION:** OBA has  
received a request from the Institutional  
Biosafety Committee at New England  
BioLabs to exempt from the  
requirements of the *NIH Guidelines*  
research with certain plasmids when  
performed in *K. lactis*. In order for a  
broad class of research to qualify for  
exemption, it must be determined by the  
NIH Director that the research does not  
pose a significant risk to human health  
or the environment (Section III–F–6).  
One way to exempt a broad class of  
research from the requirements of the  
*NIH Guidelines* is to perform the  
research in specific certified host-vector  
systems (as outlined in Appendix C of  
the *NIH Guidelines*). Currently research  
with only three certified host-vector  
systems is exempt from the *NIH  
Guidelines*. These three certified  
systems are based upon two bacterial  
genera: *Escherichia* (*E. coli* K-12) and  
*Bacillus* (*B. subtilis* or *B. licheniformis*)  
and one lower eukaryotic genus:  
*Saccharomyces* (*S. cerevisiae* or *S.  
uvarum*). In order to certify a new host-  
vector system, data as outlined in  
Appendix I–II–B of the *NIH Guidelines*  
must be submitted for review.  
Specifically, this application will be  
considered under Appendix I–II–B–1  
(Host-Vector 1 Systems Other than  
*Escherichia coli* K-12). Data to be  
considered include: (i) The strain's  
natural habitat and growth  
requirements; its physiological  
properties, particularly those related to  
its reproduction, survival, and the  
mechanisms by which it exchanges  
genetic information; the range of  
organisms with which this organism  
normally exchanges genetic information  
and the type of information that is  
exchanged; and any relevant  
information about its pathogenicity or  
toxicity; (ii) a description of the history  
of the particular strains and vectors to  
be used, including data on any  
mutations which render this organism  
less able to survive or transmit genetic  
information; and (iii) a general  
description of the range of experiments  
contemplated with emphasis on the